Notice Information
Notice Title
Hepatitis A virus (HAV) RNA & Parvovirus B19 DNA Testing Services
Notice Description
This Prior Information Notice (PIN) is a call for competition and is separate to any tender opportunity. Its purpose is to inform the market of an up-and-coming tender opportunity. NHSBT are looking for a fully integrated high throughput testing solution for the detection of hepatitis A virus (HAV) RNA and Parvovirus B19 DNA in partnership with NHSBT. Additionally, the solution must also be able to test for HBV DNA, HIV-1 RNA, HIV-2 RNA, HCV RNA, HEV RNA as contingency during a business continuity need for NHSBTs Molecular Screening Service located in Colindale London. The solution must have the relevant UKCA marking to support this ability. <br/><br/>Organisations who express an interest must declare this by 17th April 2023 date including a statement confirming their current participation in a Kit Evaluation Group (KEG) evaluation or their intention to join the KEG process. Any organisations wishing to participate in the KEG evaluation process must also submit their relevant assay Instructions For Use (IFU) by 17th April 2023 to tennille.madigan@nhsbt.nhs.uk
Lot Information
Lot 1
NHSBT requires a direct contractual relationship with either the manufacturer or any other economic operator for a complete end-to-end integrated solution, which must include all the necessary equipment, installation, maintenance, consumables, reagents, software, including an inter-operability provision with NHSBT's existing IT infrastructure, and an overall on-going support mechanism that may be required to carry out the necessary testing as stated below.
All in vitro diagnostic medical devices, for example, instruments, consumables, and reagents must be CE/UKCA marked for EDTA plasma drawn from blood donors. Other specific requirements are outlined below.
The solution:
A s Fully integrated high throughput testing solution is required for screening blood and plasma donors for HAV RNA and Parvovirus B19 DNA. Samples will be pooled prior to screening therefore pooling equipment is also required as part of the solution.
The HAV RNA and Parvovirus B19 DNA testing solution must have the ability to test EDTA plasma samples from blood & plasma donors that have been stored frozen for up to 2 years at minus 20 degrees (-20).
In addition, the solution will be required to support NHSBT's Microbiology Services Laboratory, a small specialist laboratory based in Colindale, solely in a contingency role to support NHSBT business continuity for essential screening services, therefore the testing solution MUST also have the ability to test the following as individual donations ie not pooled ) using the same analyser as for HAV and B19: HBV DNA, HIV-1 RNA, HIV-2 RNA, HCV RNA, HEV RNA in EDTA plasma samples from non-blood (e.g. stem cell, tissue) donors including those from deceased (non-heart beating) donors.
Great Britain (GB) will continue to recognise CE marking under the IVDD or IVDR until 30 June 2024 and from 1 July 2024 devices placed on the GB market must be UKCA marked under the UK MDR 2002 as amended. The end-to-end solution must be capable of producing test results in a format that can be utilised by NHSBT's host IT (PULSE) system.
HAV RNA and Parvovirus B19 DNA testing will be performed at an purpose built NHSBT laboratory based in Manchester with the following approximate number of samples per marker per year for donation screening:
Throughput: Approx: 146,000 samples per month until July 2024; July 2024 onwards 95,000 samples per month
Molecular Screening Throughput Contingency
The HAV & B19 laboratory will act as a contingency laboratory for the Molecular Screening service. As this is a contingency requirement due to a business continuity need, the numbers of tests required will be variable depending on the business continuity response. We anticipate the numbers to be relatively low compared to HAV and B19 and NHSBT will manage the work flow during a business continuity response working in partnership with the supplier to execute.
It is important that interested parties respond to this PIN, as prior KEG approval will be a mandatory requirement for any associated future tender opportunity, in-line with the requirements of the Guidelines for the Blood Transfusion Services in the United Kingdom (Red Book - https://www.transfusionguidelines.org/red-book). NHSBT will seek to understand the status of assays which would be offered with regards to KEG. Any organisations wishing to participate in the KEG evaluation process must also submit their relating assay IFUs by 17th April 2023 to tennille.madigan@nhsbt.nhs.uk
Further details on KEG and the process will be provided during Supplier Engagement. The format of Supplier Engagement will be communicated to those organisations that respond to this PIN; however, this is likely to be virtual meetings conducted via Microsoft Teams during March/April 2023. Expressions of interest should be e-mailed to tennille.madigan@nhsbt.nhs.uk by 17th April 2023.
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-03b3e0
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/007839-2023
- Current Stage
- Planning
- All Stages
- Planning
Procurement Classification
- Notice Type
- Planning Notice
- Procurement Type
- Standard
- Procurement Category
- Goods
- Procurement Method
- Not Specified
- Procurement Method Details
- Not specified
- Tender Suitability
- Not specified
- Awardee Scale
- Not specified
Common Procurement Vocabulary (CPV)
- CPV Divisions
33 - Medical equipments, pharmaceuticals and personal care products
48 - Software package and information systems
71 - Architectural, construction, engineering and inspection services
-
- CPV Codes
33000000 - Medical equipments, pharmaceuticals and personal care products
33124000 - Diagnostics and radiodiagnostic devices and supplies
33124110 - Diagnostic systems
33124130 - Diagnostic supplies
33127000 - Immuno-analysis devices
33140000 - Medical consumables
33141625 - Diagnostic kits
33696200 - Blood-testing reagents
33696500 - Laboratory reagents
48921000 - Automation system
71900000 - Laboratory services
Notice Value(s)
- Tender Value
- £5,600,000 £1M-£10M
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- Not specified
Notice Dates
- Publication Date
- 17 Mar 20232 years ago
- Submission Deadline
- Not specified
- Future Notice Date
- 3 May 2023Expired
- Award Date
- Not specified
- Contract Period
- Not specified - Not specified
- Recurrence
- Not specified
Notice Status
- Tender Status
- Planned
- Lots Status
- Planned
- Awards Status
- Not Specified
- Contracts Status
- Not Specified
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- NHS BLOOD AND TRANSPLANT
- Contact Name
- Tennille Madigan
- Contact Email
- tennille.madigan@nhsbt.nhs.uk
- Contact Phone
- +44 7795483583
Buyer Location
- Locality
- BRISTOL
- Postcode
- BS34 7QH
- Post Town
- Bristol
- Country
- England
-
- Major Region (ITL 1)
- TLK South West (England)
- Basic Region (ITL 2)
- TLK5 West of England
- Small Region (ITL 3)
- TLK52 Bath & North East Somerset and South Gloucestershire
- Delivery Location
- Not specified
-
- Local Authority
- South Gloucestershire
- Electoral Ward
- Filton
- Westminster Constituency
- Filton and Bradley Stoke
Further Information
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-03b3e0-2023-03-17T13:28:07Z",
"date": "2023-03-17T13:28:07Z",
"ocid": "ocds-h6vhtk-03b3e0",
"initiationType": "tender",
"tender": {
"id": "ocds-h6vhtk-03b3e0",
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"title": "Hepatitis A virus (HAV) RNA & Parvovirus B19 DNA Testing Services",
"status": "planned",
"classification": {
"scheme": "CPV",
"id": "33124130",
"description": "Diagnostic supplies"
},
"mainProcurementCategory": "goods",
"description": "This Prior Information Notice (PIN) is a call for competition and is separate to any tender opportunity. Its purpose is to inform the market of an up-and-coming tender opportunity. NHSBT are looking for a fully integrated high throughput testing solution for the detection of hepatitis A virus (HAV) RNA and Parvovirus B19 DNA in partnership with NHSBT. Additionally, the solution must also be able to test for HBV DNA, HIV-1 RNA, HIV-2 RNA, HCV RNA, HEV RNA as contingency during a business continuity need for NHSBTs Molecular Screening Service located in Colindale London. The solution must have the relevant UKCA marking to support this ability. <br/><br/>Organisations who express an interest must declare this by 17th April 2023 date including a statement confirming their current participation in a Kit Evaluation Group (KEG) evaluation or their intention to join the KEG process. Any organisations wishing to participate in the KEG evaluation process must also submit their relevant assay Instructions For Use (IFU) by 17th April 2023 to tennille.madigan@nhsbt.nhs.uk",
"value": {
"amount": 5600000,
"currency": "GBP"
},
"lots": [
{
"id": "1",
"description": "NHSBT requires a direct contractual relationship with either the manufacturer or any other economic operator for a complete end-to-end integrated solution, which must include all the necessary equipment, installation, maintenance, consumables, reagents, software, including an inter-operability provision with NHSBT's existing IT infrastructure, and an overall on-going support mechanism that may be required to carry out the necessary testing as stated below. <br/>All in vitro diagnostic medical devices, for example, instruments, consumables, and reagents must be CE/UKCA marked for EDTA plasma drawn from blood donors. Other specific requirements are outlined below. <br/>The solution: <br/>A s Fully integrated high throughput testing solution is required for screening blood and plasma donors for HAV RNA and Parvovirus B19 DNA. Samples will be pooled prior to screening therefore pooling equipment is also required as part of the solution. <br/>The HAV RNA and Parvovirus B19 DNA testing solution must have the ability to test EDTA plasma samples from blood & plasma donors that have been stored frozen for up to 2 years at minus 20 degrees (-20). <br/>In addition, the solution will be required to support NHSBT's Microbiology Services Laboratory, a small specialist laboratory based in Colindale, solely in a contingency role to support NHSBT business continuity for essential screening services, therefore the testing solution MUST also have the ability to test the following as individual donations ie not pooled ) using the same analyser as for HAV and B19: HBV DNA, HIV-1 RNA, HIV-2 RNA, HCV RNA, HEV RNA in EDTA plasma samples from non-blood (e.g. stem cell, tissue) donors including those from deceased (non-heart beating) donors.<br/>Great Britain (GB) will continue to recognise CE marking under the IVDD or IVDR until 30 June 2024 and from 1 July 2024 devices placed on the GB market must be UKCA marked under the UK MDR 2002 as amended. The end-to-end solution must be capable of producing test results in a format that can be utilised by NHSBT's host IT (PULSE) system. <br/>HAV RNA and Parvovirus B19 DNA testing will be performed at an purpose built NHSBT laboratory based in Manchester with the following approximate number of samples per marker per year for donation screening: <br/>Throughput: Approx: 146,000 samples per month until July 2024; July 2024 onwards 95,000 samples per month<br/>Molecular Screening Throughput Contingency <br/>The HAV & B19 laboratory will act as a contingency laboratory for the Molecular Screening service. As this is a contingency requirement due to a business continuity need, the numbers of tests required will be variable depending on the business continuity response. We anticipate the numbers to be relatively low compared to HAV and B19 and NHSBT will manage the work flow during a business continuity response working in partnership with the supplier to execute.<br/><br/>It is important that interested parties respond to this PIN, as prior KEG approval will be a mandatory requirement for any associated future tender opportunity, in-line with the requirements of the Guidelines for the Blood Transfusion Services in the United Kingdom (Red Book - https://www.transfusionguidelines.org/red-book). NHSBT will seek to understand the status of assays which would be offered with regards to KEG. Any organisations wishing to participate in the KEG evaluation process must also submit their relating assay IFUs by 17th April 2023 to tennille.madigan@nhsbt.nhs.uk<br/>Further details on KEG and the process will be provided during Supplier Engagement. The format of Supplier Engagement will be communicated to those organisations that respond to this PIN; however, this is likely to be virtual meetings conducted via Microsoft Teams during March/April 2023. Expressions of interest should be e-mailed to tennille.madigan@nhsbt.nhs.uk by 17th April 2023.",
"status": "planned"
}
],
"items": [
{
"id": "1",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33124130",
"description": "Diagnostic supplies"
},
{
"scheme": "CPV",
"id": "33124000",
"description": "Diagnostics and radiodiagnostic devices and supplies"
},
{
"scheme": "CPV",
"id": "33127000",
"description": "Immuno-analysis devices"
},
{
"scheme": "CPV",
"id": "71900000",
"description": "Laboratory services"
},
{
"scheme": "CPV",
"id": "33696200",
"description": "Blood-testing reagents"
},
{
"scheme": "CPV",
"id": "48921000",
"description": "Automation system"
},
{
"scheme": "CPV",
"id": "33124110",
"description": "Diagnostic systems"
},
{
"scheme": "CPV",
"id": "33141625",
"description": "Diagnostic kits"
},
{
"scheme": "CPV",
"id": "33696500",
"description": "Laboratory reagents"
},
{
"scheme": "CPV",
"id": "33140000",
"description": "Medical consumables"
},
{
"scheme": "CPV",
"id": "33000000",
"description": "Medical equipments, pharmaceuticals and personal care products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "Manchester"
},
"relatedLot": "1"
}
],
"communication": {
"futureNoticeDate": "2023-05-04T00:00:00+01:00",
"atypicalToolUrl": "https://health-family.force.com/s/Welcome"
}
},
"parties": [
{
"id": "GB-FTS-18293",
"name": "NHS Blood and Transplant",
"identifier": {
"legalName": "NHS Blood and Transplant"
},
"address": {
"streetAddress": "500 North Bristol Park",
"locality": "Bristol",
"region": "UKK11",
"postalCode": "BS34 7QH",
"countryName": "United Kingdom"
},
"contactPoint": {
"name": "Tennille Madigan",
"telephone": "+44 7795483583",
"email": "tennille.madigan@nhsbt.nhs.uk"
},
"roles": [
"buyer"
],
"details": {
"url": "https://www.nhsbt.nhs.uk/",
"buyerProfile": "https://www.nhsbt.nhs.uk/",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"id": "BODY_PUBLIC",
"description": "Body governed by public law"
},
{
"scheme": "COFOG",
"id": "07",
"description": "Health"
}
]
}
}
],
"buyer": {
"id": "GB-FTS-18293",
"name": "NHS Blood and Transplant"
},
"language": "en"
}